ImmuPharma plc (LON:IMM – Get Free Report)’s share price traded up 13.4% during trading on Wednesday . The stock traded as high as GBX 10.80 and last traded at GBX 10.50. 7,242,426 shares traded hands during mid-day trading, a decline of 10% from the average session volume of 8,073,004 shares. The stock had previously closed at GBX 9.26.
ImmuPharma Stock Performance
The firm has a market capitalization of £52.79 million, a PE ratio of -11.80 and a beta of 1.53. The firm’s 50-day moving average is GBX 10.98 and its 200 day moving average is GBX 5.43.
About ImmuPharma
ImmuPharma PLC (LSE AIM: IMM) is a specialty biopharmaceutical company that discovers and develops peptide-based therapeutics. The Company’s portfolio includes novel peptide therapeutics for autoimmune diseases and anti-infectives. The lead program, P140 (Lupuzor™), is a first-in class autophagy immunomodulator for the treatment of Lupus and preclinical analysis suggest therapeutic activity for many other autoimmune diseases that share the same autophagy mechanism of action.
Read More
- Five stocks we like better than ImmuPharma
- The Basics of Support and Resistance
- Rare Earth Stocks: The Truce That Isn’t a Truce
- How to buy stock: A step-by-step guide for beginners
- Carving Up Profits: 3 Food Stocks on the Thanksgiving Table
- 10 Best Airline Stocks to Buy
- C3.ai’s Reset: Why New Leadership Could Spark a Turnaround
Receive News & Ratings for ImmuPharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ImmuPharma and related companies with MarketBeat.com's FREE daily email newsletter.
